Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.

9 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

Ascension Orthopedics launches PyroTITAN Humeral Resurfacing Arthroplasty System

Ascension Orthopedics, Inc., a leader in orthopedic extremity implants, announces the international market launch of the PyroTITAN™ Humeral Resurfacing Arthroplasty System at the American Academy of Orthopaedic Surgeons Annual Conference in New Orleans, LA, March 9-13, 2010. Designed to meet the unique soft tissue biocompatibility requirements of the shoulder joint, the PyroTITAN humeral resurfacing implant is the first commercially-available, human shoulder arthroplasty prosthesis made of PyroCarbon.

8 Mar 2010

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.

8 Mar 2010

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

As part of the Salmonella Montevideo investigation, the Food and Drug Administration has been actively investigating the supply chain of black and red pepper supplied to Daniele International Inc., Pascoag, R.I.

6 Mar 2010

UCB Rheumatoid Arthritis Family Scholarship applications open until March 19, 2010

Applications are being accepted until March 19, 2010 for the UCB Rheumatoid Arthritis Family Scholarship. These scholarships are for rheumatoid arthritis patients or their immediate family members. Winners are awarded up to $10,000 to continue their studies at an accredited institution of higher education in the U.S.

6 Mar 2010

Salmonella Tennessee in Basic Food Flavors' HVP: FDA taking steps to protect consumers

The U.S. Food and Drug Administration is taking steps to protect the public following the early identification of Salmonella Tennessee in one company's supply of hydrolyzed vegetable protein (HVP). This is a common ingredient used most frequently as a flavor enhancer in many processed foods, including soups, sauces, chilis, stews, hot dogs, gravies, seasoned snack foods, dips and dressings.

6 Mar 2010

Possible Salmonella contamination: Mincing Overseas Spice recalls two lots of black pepper

Mincing Overseas Spice Company of Dayton, New Jersey announced today that it is recalling black pepper Lots 3258 and 3309 because of possible contamination with Salmonella.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

Dr. Marc McKee, of McGill's Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee's research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth.

6 Mar 2010

RWJF awards $480,000 grant to improve clinical care for low-weight babies

Researchers at UC Irvine and the Charles Drew University of Medicine and Science (CDU) will monitor the day-to-day health of low-birth-weight babies and their parents as part of a comprehensive initiative designed to combat chronic illnesses associated with low-weight births.

5 Mar 2010

FDA takes steps to protect consumers from potential Salmonella infection

5 Mar 2010

Proper treatment can help control psoriasis in most cases

For the approximately 7.5 million Americans affected by psoriasis, the thick, red, scaly, itchy plaques it causes only scratch the surface when it comes to the overall implications of this disease. Now, ongoing research linking psoriasis to other serious medical conditions and the incredible toll it can take on a person's overall quality of life are shifting the way psoriasis is viewed - from a common skin disease to a complex systemic condition.

5 Mar 2010

Chikungunya: Experimental vaccine successfully tested in monkeys

Imagine a mosquito-borne virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the Indian Ocean, Africa and northern Italy. Although seldom fatal, it causes highly painful arthritis-like symptoms that can linger for months or even years. It's capable of adapting to spread through a mosquito species common in much of North America. And no vaccine or treatment exists to protect humans from its effects.

5 Mar 2010

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

5 Mar 2010

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

Data evaluating the efficacy and safety of STELARA™ (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Fla., from March 5-9, 2010.

5 Mar 2010

FDA approves CSL Behring's Hizentra for PI

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for HizentraTM, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PI). A once weekly immunoglobulin (Ig) replacement therapy, Hizentra provides effective protection against infection by maintaining a steady and normal level of immunoglobulin in the body.

4 Mar 2010

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, is on a mission to help patients obtain the financial assistance they need to purchase life-saving drugs for such illnesses as cancer, HIV/AIDS and Hepatitis C, as well as drugs for Multiple Sclerosis, kidney disease and other chronic conditions.

4 Mar 2010

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

The signaling molecule CD95L, known as "death messenger," causes an inflammatory process in injured tissue after spinal cord injuries and prevents its healing. This discovery was published by scientists of the German Cancer Research Center. In mice, the researchers found out that if they switch off CD95L, the injured spinal cord heals and the animals regain better ability to move. Therefore, substances which block the death messenger might offer a new approach in the treatment of severe inflammatory diseases.

4 Mar 2010

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

A groundbreaking new report from the American Autoimmune Related Diseases Association, examining the current state of autoimmune disease (AD) and its economic and social impact globally and in the U.S., was released today at the National Autoimmune Diseases Summit: The Global State of Autoimmunity Today, held to kick-off National Autoimmune Disease Awareness Month.

4 Mar 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Ascension Orthopedics launches PyroTITAN Humeral Resurfacing Arthroplasty System

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

UCB Rheumatoid Arthritis Family Scholarship applications open until March 19, 2010

Salmonella Tennessee in Basic Food Flavors' HVP: FDA taking steps to protect consumers

Possible Salmonella contamination: Mincing Overseas Spice recalls two lots of black pepper

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

McGill, Enobia Pharma collaborate to develop treatments for serious genetic bone diseases

RWJF awards $480,000 grant to improve clinical care for low-weight babies

FDA takes steps to protect consumers from potential Salmonella infection

Proper treatment can help control psoriasis in most cases

Chikungunya: Experimental vaccine successfully tested in monkeys

KAPIDEX to be marketed as DEXILANT in the U.S.

Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented

FDA approves CSL Behring's Hizentra for PI

Diplomat Specialty Pharmacy to help patients obtain financial assistance to purchase life-saving drugs

Severe inflammatory diseases: Blocking "death messenger" might be a promising treatment

AARDA report examining current state of AD released at the National Autoimmune Diseases Summit

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in